JPMorgan Chase & Co’s Oric Pharmaceuticals ORIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.6M | Buy |
1,335,448
+1,299,799
| +3,646% | +$13.2M | ﹤0.01% | 1990 |
|
|
2025
Q1 | $199K | Buy |
35,649
+1,913
| +6% | +$10.7K | ﹤0.01% | 4435 |
|
|
2024
Q4 | $272K | Sell |
33,736
-1,515
| -4% | -$12.2K | ﹤0.01% | 4411 |
|
|
2024
Q3 | $361K | Buy |
35,251
+1,279
| +4% | +$13.1K | ﹤0.01% | 4195 |
|
|
2024
Q2 | $240K | Buy |
33,972
+2,171
| +7% | +$15.3K | ﹤0.01% | 4193 |
|
|
2024
Q1 | $437K | Sell |
31,801
-6,374
| -17% | -$87.6K | ﹤0.01% | 4034 |
|
|
2023
Q4 | $351K | Buy |
38,175
+11,405
| +43% | +$105K | ﹤0.01% | 4100 |
|
|
2023
Q3 | $162K | Sell |
26,770
-4,254
| -14% | -$25.7K | ﹤0.01% | 4347 |
|
|
2023
Q2 | $241K | Buy |
31,024
+29,864
| +2,574% | +$232K | ﹤0.01% | 4180 |
|
|
2023
Q1 | $6K | Buy |
1,160
+400
| +53% | +$2.07K | ﹤0.01% | 5358 |
|
|
2022
Q4 | $4K | Sell |
760
-12,984
| -94% | -$68.3K | ﹤0.01% | 5267 |
|
|
2022
Q3 | $44K | Buy |
13,744
+7,822
| +132% | +$25K | ﹤0.01% | 4742 |
|
|
2022
Q2 | $27K | Sell |
5,922
-13,732
| -70% | -$62.6K | ﹤0.01% | 5005 |
|
|
2022
Q1 | $105K | Buy |
19,654
+3,794
| +24% | +$20.3K | ﹤0.01% | 4720 |
|
|
2021
Q4 | $233K | Sell |
15,860
-6,080
| -28% | -$89.3K | ﹤0.01% | 4459 |
|
|
2021
Q3 | $459K | Buy |
21,940
+5,505
| +33% | +$115K | ﹤0.01% | 4014 |
|
|
2021
Q2 | $291K | Buy |
16,435
+4,761
| +41% | +$84.3K | ﹤0.01% | 4299 |
|
|
2021
Q1 | $286K | Buy |
11,674
+1,723
| +17% | +$42.2K | ﹤0.01% | 4318 |
|
|
2020
Q4 | $337K | Buy |
9,951
+6,705
| +207% | +$227K | ﹤0.01% | 3952 |
|
|
2020
Q3 | $75K | Sell |
3,246
-2,971
| -48% | -$68.6K | ﹤0.01% | 4173 |
|
|
2020
Q2 | $210K | Buy |
+6,217
| New | +$210K | ﹤0.01% | 3645 |
|